Wolters Kluwer opens lobby shop in Washington

Share this article:

Wolters Kluwer Health has appointed its first VP-government affairs as the publishing giant seeks to head off state restrictions on commercial use of prescription data.

The company named longtime healthcare lobbyist Cathy Betz to the position. Betz has been a partner in her husband's Washington, DC, health policy consulting firm, Robert Betz Associates, for a quarter-century.

Wolters Kluwer's Healthcare Analytics unit, part of its Pharma Solutions business, offers prescribing pattern data. Last year, 23 states introduced legislation to restrict the sale or use of such data. In addition, Congress has been showing increasing interest of late in the potential influence of pharmaceutical firms on medical journals and CME. In August, the company joined IMS Health and Verispan in lawsuits aimed at blocking Maine and Vermont from implementing laws, slated to take effect in 2008, that would curb the collection and disclosure of physician prescribing information.

In addition to prescriber data access, “We're focusing on any e-health initiatives and this whole transparency issue in general on the state and federal level,” said Betz. “That's what's interesting about these [state] initiatives – they're really going against the trend towards transparency and I think that's why they'll fail. At the federal level, they understand that, and they're moving towards more access to more data, more information and more transparency as a way to improve health outcomes.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...